ZURICH (dpa-AFX Broker) - The major Swiss bank UBS has left its rating for Merck KGaA at "Buy" with a target price of 186 euros. The failure of Xevinapent is a bitter disappointment after the good Phase II data, wrote analyst Matthew Weston on Tuesday in view of the discontinued Phase III study. The Darmstadt-based company now no longer has an advanced test candidate in the pipeline in the pharmaceutical sector - and this with the patent expiry of Mavenclad expected to be in October 2026. 2025, however, the end of Xevinapant should have a positive impact on pharmaceutical margins in the short term./ag/tih

Publication of the original study: 25.06.2024 / 06:14 / GMT

First dissemination of the original study: 25.06.2024 / 06:14 / GMT

-----------------------

dpa-AFX Broker - the Trader News from dpa-AFX

-----------------------